Serum and BALF levels of YKL-40 in patients with alveolar proteinosis Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010
Serum IFN-γ and TNF-α levels in pulmonary tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 456s Year: 2005
Serum chitotriosidase levels in granulomatous lung disorders Source: Annual Congress 2006 - Clinical features and disease markers of sarcoidosis Year: 2006
Serum lipid levels in patients with bronchiectasis Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi Year: 2008
Correlation of HRCT proven inflammatory changes with serum levels of ACE, sIL-2r and calciuria in pulmonary sarcoidosis Source: Eur Respir J 2003; 22: Suppl. 45, 226s Year: 2003
Serum KL-6 level and DTPA clearance in systemic sclerosis patients Source: Eur Respir J 2002; 20: Suppl. 38, 587s Year: 2002
Serum levels of IL-10 and IL-12 i patients with pulmonary sarcoidosis Source: Annual Congress 2009 - Inflammation and airways Year: 2009
High serum levels of YKL-40 in IPF Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology Year: 2008
Serum KL-6 identifies ILD patients with a progressive fibrosing phenotype Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020
Elevated serum S100A4 levels in patients with silicosis Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019
Serum levels of IL-10 and IL-12p40 in pulmonary sarcoidosis Source: Eur Respir J 2007; 30: Suppl. 51, 139s Year: 2007
Serum markers of acute sarcoidosis. Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases Year: 2020
Serum 1,25(OH)2D levels and arterial hypertension (AH) in sarcoidosis patients Source: Annual Congress 2009 - Sarcoidosis and profiles of other diffuse parenchymal lung disease Year: 2009
Discrepant elevation of sIL-2R levels in sarcoidosis patients with renal insufficiency Source: Eur Respir J 2015; 46: 277-280 Year: 2015
Serum KL-6 level is increased in patients with pneumocystis pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 101s Year: 2006
Serum KL-6 as a marker of disease progression in SSc-ILD Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018
Serum KL-6, SP-D and MMP-2 as diagnostic biomarkers in asbestosis and silicosis Source: International Congress 2017 – Silicosis has not gone away Year: 2017
Serum neopterin and IL-6 as biomarkers in patients with COPD. Source: International Congress 2017 – Novel molecular and genetic targets in COPD Year: 2017
Elevated levels of serum SP-A in chronic eosinophilic pneumonia Source: Eur Respir J 2001; 18: Suppl. 33, 409s Year: 2001
YKL-40 and KL-6 in serum and sputum samples of patients diagnosed with hypersensitivity pneumonitis. Source: International Congress 2019 – Environment, work and respiratory health in occupational and environmental lung diseases Year: 2019